Satyam Generic Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.94 M
as on 16-11-2024
- Company Age 24 Year, 24 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.33 Cr
as on 16-11-2024
- Revenue 19.75%
(FY 2023)
- Profit 75.77%
(FY 2023)
- Ebitda 619.19%
(FY 2023)
- Net Worth 26.82%
(FY 2023)
- Total Assets 8.37%
(FY 2023)
About Satyam Generic Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.94 M.
The company currently has active open charges totaling ₹5.33 Cr.
Dinesh Singh, Brijesh Singh, and Dhroov Singh serve as directors at the Company.
- CIN/LLPIN
U51397MH2000PTC129773
- Company No.
129773
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Nov 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Satyam Generic Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinesh Singh  | Director | 27-Nov-2000 | Current |
| Brijesh Singh | Director | 27-Nov-2000 | Current |
| Dhroov Singh | Director | 15-Mar-2022 | Current |
Financial Performance of Satyam Generic Pharma.
Satyam Generic Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.75% increase. The company also saw a substantial improvement in profitability, with a 75.77% increase in profit. The company's net worth Soared by an impressive increase of 26.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Satyam Generic Pharma?
In 2023, Satyam Generic Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Prevego Healthcare & Research Private LimitedActive 6 years 7 monthsBrijesh Singh is a mutual person
Chandra-Corbox Packaging Private LimitedActive 27 years 5 monthsDinesh Singh and Brijesh Singh are mutual person
- Sundaram Pharma Private LimitedActive 20 years 1 month
Dinesh Singh, Brijesh Singh and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 May 2012 | ₹2.90 Cr | Open |
Ing Vysya Bank Limited Creation Date: 30 Jul 2009 | ₹1.25 Cr | Open |
Indusind Bank Limited Creation Date: 18 Nov 2006 | ₹7.50 M | Open |
How Many Employees Work at Satyam Generic Pharma?
Unlock and access historical data on people associated with Satyam Generic Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Satyam Generic Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Satyam Generic Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
